ShanghaiMay 22, 2026 /PRNewswire/ — On May 15, 2026, the Second International Organoid Conference was grandly held in Shanghai. Professor Hans Clevers, a member of the Royal Netherlands Academy of Arts and Sciences and renowned as the “Father of Organoids“, attended the event in person to share the latest advancements in organoid technology. Notably, for the first time, he introduced the organoid platform construction efforts being actively promoted by the China Resources Life Sciences Research Institute in his capacity as its Honorary President, showcasing a new paradigm of deep integration between globally leading academic forces and Chinese industrial translation.
Professor Hans Clevers delivers a speech at the Second International Organoid Conference
As a key sponsor of the conference, Beckman Coulter Life Sciences provided full support for this academic event. This appearance was not an isolated market activity — it was underpinned by a deep strategic collaboration between its parent organization, the Danaher Life Sciences Platform, and the China Resources Life Sciences Research Institute, as well as Beckman Coulter Life Sciences’ mature solutions in the organoid field.
Beckman Coulter Life Sciences showcases its solutions in organoid research
Danaher and China Resources Sign Strategic Cooperation Memorandum
As early as March this year, the “2026 China Resources Life Sciences Research Institute Frontier Technology Innovation Forum — International Symposium on Organoid and Organ-on-a-Chip Technology Development and Application,” co-organized by the China Resources Life Sciences Research Institute and Danaher China Life Sciences Platform, was held in the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone (Shenzhen Park). Professor Hans Clevers attended the event and delivered a keynote report, during which he was officially appointed as Honorary President of the China Resources Life Sciences Research Institute.
At the same event, Danaher China Life Sciences Platform and China Resources Life Sciences Research Institute signed a strategic cooperation memorandum, committing to comprehensive and in-depth collaboration in the organoid and organ-on-a-chip fields, covering application scenario exploration, industrial ecosystem building, and talent cultivation. Mr. Hu Xiangyu, President of Danaher China Life Sciences Platform, noted that once organoid-based drugs receive approval, it would boost regulatory and industrial confidence, creating new opportunities for CROs and CDMOs.
As a core brand in the life sciences sector under Danaher Group, Beckman Coulter Life Sciences, leveraging decades of technical expertise in automated liquid handling, provides end-to-end automated solutions for organoid research, from cell seeding and media exchange to drug screening.
Addressing Organoid Research Pain Points: Beckman Coulter Life Sciences Automated Liquid Handling Solutions
Although organoid models offer structural and functional advantages close to primary tissues, they have long faced three major challenges in practical research: difficulty in uniformly generating 3D structures, poor reproducibility in cell seeding, and challenges in adapting to high-throughput screening. Beckman Coulter Life Sciences’ Biomek series automated workstations are designed to address these issues.
- End-to-End Automation: From cell seeding, growth factor addition, and media exchange to cell fixation, staining, compound treatment, and endpoint detection, models like the Biomek i7 enable one-click automated operations, significantly enhancing experimental consistency and reproducibility.
- Modular Flexible Expansion: Integrates tilting modules, shaking modules, temperature control modules, on-deck incubators, and benchtop centrifuges, enabling continuous microfluidic channel perfusion and timed media changes. An on-deck camera allows real-time monitoring of experimental processes, ensuring full workflow visualization.
- Organ-on-a-Chip Detection Automation: In collaboration with MIMETAS and Molecular Devices, Beckman Coulter Life Sciences leverages the OrganoPlate® microfluidic platform and high-content imaging to achieve high-throughput, high-reproducibility detection in complex 3D studies, such as angiogenesis models.
- Miniaturized Drug Sensitivity Testing: In synergy with the Echo 650 acoustic liquid handling system, it enables nanoliter-level precise liquid transfer (2.5 nL to 25 μL), significantly saving compounds and reagents, providing an ideal solution for miniaturized organoid drug sensitivity testing.
From Academic Leadership to Industrial Implementation: Beckman Coulter Life Sciences Defines New Standards for Organoid Automation
As a key member of the Danaher Life Sciences Platform, Beckman Coulter Life Sciences’ automated liquid handling solutions are providing a solid technical foundation for numerous organoid research institutions, helping organoid research transition from manual operations to standardization and high throughput.
Looking ahead, with the continued academic leadership of renowned scientists like Professor Hans Clevers, organoid technology is poised to move toward broader application scenarios. Beckman Coulter Life Sciences will continue to leverage its Biomek series automated workstations as a core offering, providing global organoid researchers with efficient, reliable, and scalable automation tools, jointly empowering precision medicine and new drug development.